EA201100028A1 - Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh) - Google Patents

Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)

Info

Publication number
EA201100028A1
EA201100028A1 EA201100028A EA201100028A EA201100028A1 EA 201100028 A1 EA201100028 A1 EA 201100028A1 EA 201100028 A EA201100028 A EA 201100028A EA 201100028 A EA201100028 A EA 201100028A EA 201100028 A1 EA201100028 A1 EA 201100028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dhodh
metotrexat
dihydroorototdehydrogenase
inhibitors
combinations including
Prior art date
Application number
EA201100028A
Other languages
English (en)
Other versions
EA020193B1 (ru
Inventor
Нурия Годессарт Марина
Мария Пилар Пискуета Лаланса
Original Assignee
Альмираль, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Альмираль, С.А. filed Critical Альмираль, С.А.
Publication of EA201100028A1 publication Critical patent/EA201100028A1/ru
Publication of EA020193B1 publication Critical patent/EA020193B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Комбинация, включающая (а) метотрексат и (б) ингибитор DHODH, не обладающий гепатотоксичностью.
EA201100028A 2008-06-20 2009-06-18 Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh) EA020193B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08382022A EP2135610A1 (en) 2008-06-20 2008-06-20 Combination comprising DHODH inhibitors and methotrexate
PCT/EP2009/004404 WO2009153043A1 (en) 2008-06-20 2009-06-18 Combinations comprising methotrexate and dhodh inhibitors

Publications (2)

Publication Number Publication Date
EA201100028A1 true EA201100028A1 (ru) 2011-08-30
EA020193B1 EA020193B1 (ru) 2014-09-30

Family

ID=39930498

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100028A EA020193B1 (ru) 2008-06-20 2009-06-18 Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)

Country Status (35)

Country Link
US (1) US8865728B2 (ru)
EP (2) EP2135610A1 (ru)
JP (1) JP5507551B2 (ru)
KR (1) KR101675601B1 (ru)
CN (1) CN102065866B (ru)
AR (1) AR072174A1 (ru)
AU (1) AU2009259625B2 (ru)
BR (1) BRPI0909995A2 (ru)
CA (1) CA2728976C (ru)
CL (1) CL2010001359A1 (ru)
CO (1) CO6321267A2 (ru)
CY (1) CY1119643T1 (ru)
DK (1) DK2296663T3 (ru)
EA (1) EA020193B1 (ru)
ES (1) ES2641168T3 (ru)
HR (1) HRP20171667T1 (ru)
HU (1) HUE036639T2 (ru)
IL (1) IL209267A (ru)
LT (1) LT2296663T (ru)
ME (1) ME02903B (ru)
MX (1) MX2010013409A (ru)
MY (1) MY155249A (ru)
NO (1) NO2296663T3 (ru)
NZ (1) NZ589089A (ru)
PE (1) PE20110149A1 (ru)
PL (1) PL2296663T3 (ru)
PT (1) PT2296663T (ru)
RS (1) RS56584B1 (ru)
SG (2) SG189810A1 (ru)
SI (1) SI2296663T1 (ru)
TW (1) TWI440462B (ru)
UA (1) UA114388C2 (ru)
UY (1) UY31897A1 (ru)
WO (1) WO2009153043A1 (ru)
ZA (1) ZA201008041B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
BRPI0921258A2 (pt) * 2008-11-07 2018-10-23 4Sc Ag terapia combinatória compreendendo inibidor de dhodh e metotrexato para o tratamento de doença autoimune
EP2210615A1 (en) * 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
RU2611341C2 (ru) * 2011-08-30 2017-02-21 Тояма Кемикал Ко., Лтд. Способ увеличения эффективности терапии аутоиммунных заболеваний, таких как ревматоидный артрит
EP2594271A1 (en) * 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
CN103315985A (zh) * 2013-05-16 2013-09-25 南京市鼓楼医院 Fingolimod在制备抑制肝癌肝内转移药物中的应用
EP3368896A1 (en) * 2015-10-30 2018-09-05 FMC Corporation Dihydroorotate dehydrogenase inhibitor compositions effective as herbicides
CN108524482B (zh) 2017-03-02 2022-11-25 中国科学院上海药物研究所 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
WO2020225330A1 (en) 2019-05-07 2020-11-12 Universität Hamburg Dhodh inhibitors and their use as antiviral agents
US20230390276A1 (en) * 2020-10-15 2023-12-07 Aslan Pharmaceuticals Pte. Ltd. Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
EP4119138A1 (en) 2021-07-12 2023-01-18 Universität Hamburg Dhodh inhibitors and their use as antiviral agents
WO2023204754A1 (en) * 2022-04-21 2023-10-26 Aslan Pharmaceuticals Pte Ltd Treatment of autoimmune skin disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181896C (zh) 1995-06-21 2004-12-29 索福泰克两合公司 带整体计量装置的药筒和药粉吸入器
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
CA2375551A1 (en) 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
DE60226855D1 (de) 2001-04-05 2008-07-10 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
WO2002102374A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Amine salt of an integrin receptor antagonist
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
AU2003300530A1 (en) * 2002-12-23 2004-07-14 4Sc Ag Dhodh-inhibitors and method for their identification
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
SE0400234D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
CA2567602A1 (en) 2004-05-21 2006-01-05 The Uab Research Foundation Compositions and methods relating to pyrimidine synthesis inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
SG142305A1 (en) 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2118051B1 (en) * 2007-02-06 2011-05-04 Chelsea Therapeutics, Inc. New compounds, methods for their preparation and use thereof
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
TW201000103A (en) 2010-01-01
KR101675601B1 (ko) 2016-11-11
IL209267A (en) 2017-07-31
CN102065866B (zh) 2014-03-26
JP5507551B2 (ja) 2014-05-28
SI2296663T1 (sl) 2017-11-30
AU2009259625A1 (en) 2009-12-23
CL2010001359A1 (es) 2011-04-08
AU2009259625B2 (en) 2015-01-15
PE20110149A1 (es) 2011-03-07
CY1119643T1 (el) 2018-04-04
MX2010013409A (es) 2010-12-22
SG10201609515RA (en) 2017-01-27
SG189810A1 (en) 2013-05-31
WO2009153043A1 (en) 2009-12-23
NO2296663T3 (ru) 2018-01-13
ES2641168T3 (es) 2017-11-08
CA2728976A1 (en) 2009-12-23
HRP20171667T1 (hr) 2017-12-15
AR072174A1 (es) 2010-08-11
ZA201008041B (en) 2011-06-29
CO6321267A2 (es) 2011-09-20
PT2296663T (pt) 2017-09-11
US8865728B2 (en) 2014-10-21
IL209267A0 (en) 2011-01-31
EP2296663A1 (en) 2011-03-23
LT2296663T (lt) 2017-09-25
DK2296663T3 (en) 2017-10-30
PL2296663T3 (pl) 2018-04-30
BRPI0909995A2 (pt) 2015-10-20
US20110129445A1 (en) 2011-06-02
NZ589089A (en) 2012-12-21
RS56584B1 (sr) 2018-02-28
CN102065866A (zh) 2011-05-18
EP2135610A1 (en) 2009-12-23
TWI440462B (zh) 2014-06-11
HUE036639T2 (hu) 2018-07-30
ME02903B (me) 2018-10-20
EA020193B1 (ru) 2014-09-30
CA2728976C (en) 2017-10-17
UA114388C2 (uk) 2017-06-12
MY155249A (en) 2015-09-30
KR20110036530A (ko) 2011-04-07
JP2011524392A (ja) 2011-09-01
EP2296663B1 (en) 2017-08-16
UY31897A1 (es) 2009-08-31

Similar Documents

Publication Publication Date Title
EA201100028A1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EA201270149A1 (ru) Ингибиторы bace
SMT201700037B (it) Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici
BRPI1005169A2 (pt) combinação de (a) metotrexato e (b) um inibidor de dhodh não-hepatotóxico, uso de uma combinação, produto, conjunto, embalagem e método de tratamento
EA201070856A1 (ru) Кристаллические формы диметоксидоцетаксела и способы их получения
SMT201400179B (it) 1,2,5-Ossadiazoli come inibitori di indoleamina 2,3-diossigenasi
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201390465A1 (ru) Двойные ингибиторы мэн и фрэс для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
UY34848A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
EA201390214A1 (ru) Гетероарилы и их применение
BRPI0910307A2 (pt) inibidores de hiv integrase
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
EA200900441A1 (ru) Способы и интермедиаты для получения ингибиторов интегразы
EA201270378A1 (ru) Хиназолины в качестве ингибиторов калиевых каналов
MY144590A (en) Glutamate aggrecanase inhibitors
ATE459624T1 (de) Inhibitoren der reversen transkriptase des hiv
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
EA200801739A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
SV2010003648A (es) Inhibidores del receptor de quimioquinas cxcr3
EA200801852A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
EA201490450A1 (ru) Новые ингибиторы ферментов